Judge Declares Zantac Recusal Issue Over in Philadelphia

Judge Joshua Roberts ruled the recusal dispute resolved after Apotex settled the only case against it, while Keller Postman appeals.

Updated on Nov. 13, 2026 in Cancer

Stone and granite civic courthouse facade on an urban street under overcast daylight, with tall columns and deep-set windows and no people visible.
Philadelphia Judge Joshua Roberts ruled on Nov. 9 that the recusal dispute over his Zantac cases is over, while plaintiffs' firm Keller Postman appeals. AI Illustration. Upload story photo >

Philadelphia Judge Joshua Roberts announced on Nov. 9 that the Apotex case had settled and declared the recusal issue over in the Zantac cases. Keller Postman has filed an appeal with the state Superior Court over Roberts' refusal to step down.

Why it matters

The dispute centers on a spousal link between Roberts and a partner at Blank Rome, which represented Apotex, and the outcome could shape how the Zantac litigation is overseen in Philadelphia. With 609 cases still awaiting a ruling on expert testimony, the pretrial rulings in the mass tort remain consequential for residents and patients in the region.

Judges in Delaware and Florida have tossed more than 100,000 Zantac claims over unreliable expert testimony, while 609 lawsuits still await a ruling on whether disqualified experts can testify about NDMA formation from ranitidine. The status of those 609 rulings remains unresolved.

The players

Joshua Roberts

Joshua Roberts is a Philadelphia judge who oversees pretrial matters in the Zantac mass tort and will not preside over trials.

Keller Postman

Keller Postman is a plaintiffs' law firm that moved for Roberts' recusal and has filed an appeal with the state Superior Court.

Apotex

Apotex is a generic drug manufacturer that settled the only case against it in the Hilbert matter, a minor's claim.

Valisure LLC

Valisure LLC is a laboratory whose 2019 testing of ranitidine underlies the Zantac lawsuits, and which the FDA said used unreliable methods.

The details

Plaintiffs' lawyers at Keller Postman moved for Roberts' recusal from all Zantac cases in Philadelphia's Complex Litigation Center, citing his wife Shannon McClure's partnership at Blank Rome, which represented Apotex. Roberts oversees pretrial matters in the Zantac mass tort and will not preside over trials, and he has refused to step down. The lawsuits are based on testing by Valisure LLC, which the FDA said used unreliable methods, and Valisure detected no NDMA in the drug under normal human conditions.

Timeline

  1. 2019: Valisure published testing claiming Zantac contained NDMA-forming ranitidine.

  2. Nov. 9, 2026: Roberts announced the Apotex settlement and declared the recusal issue over.

Health Landscape

The Philadelphia litigation follows the pattern set by Delaware and Florida courts, which tossed more than 100,000 Zantac claims over unreliable expert testimony. Whether Philadelphia's pending expert-testimony rulings align with those earlier decisions will shape how the broader Zantac mass tort proceeds.

Patients who took ranitidine may be affected by how the 609 pending expert-testimony rulings are decided, since those rulings determine whether their claims can move forward. Residents seeking to understand their options should track the Philadelphia court docket and any Superior Court action on the recusal appeal.

The takeaway

Court rulings on expert testimony are shaping which Zantac claims survive, and the outcome of the recusal appeal and the 609 pending rulings will determine how the Philadelphia litigation proceeds.

Further reading

For background on the disease at the center of these claims, see the Cancer section.

Source note: This article includes information reported by Legal Newsline.